Rune Labs, a San Francisco-based neuromodulation startup, has raised $22.8 million in Series A financing to continue shaping the future of neuromodulation and brain therapyy
The funding round was led by Eclipse Ventures and counted with participation from current investors such as DigiTx Partners and Moment Ventures. Justin Butler, Partner at Eclipse, will be joining the Rune Labs Board of Directors as a result of this round, which also brings the total funding raised by the startup to $29.3 million. Justin Butler, Partner at Eclipse, said about the firm’s participation:
“Rune Labs’ software platform aggregates the myriad of brain data into an integrated environment, enabling precision neuromedicine. It is enabling new approaches to treating neurodegenerative and psychiatric diseases, allowing clinicians to personalize patient care. We’ve seen a new class of data-driven precision medicine approaches make huge progress in oncology, and the Rune Labs platform will be the first to enable similar breakthroughs in neurology.”
Rune Labs was founded to extend and improve the therapeutic approach for patients with neurodegenerative and psychiatric diseases. The technology developed by the startup allows care providers to take advantage of complex therapy algorithms that integrate electrophysiology, brain imaging, and device data with clinical labels and wearable data to improve clinical treatment. Brian Pepin, Founder and CEO of Rune Labs, referred to how the round will boost these efforts by stating:
“Since our founding in 2018, we have made substantial progress in the development and implementation of our brain data software platform. This financing will enable us to expand the number of patients, clinicians, and researchers using our platform to inform precision therapy development and delivery for patients with Parkinson’s disease, multiple sclerosis and depression.”
With approximately 60.000 Americans being diagnosed with Parkinson’s disease and other neurodegenerative disorders, finding effective treatments has become a major concern among experts. By developing and expanding its precision medicine solutions, the neuromodulation startup believes it can improve clinical care and make brain data more useful at a large scale.